These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 26924424)

  • 1. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
    Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
    Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
    O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
    J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
    Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
    Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The \textit{BRAF} V600E mutation in single- institution study of Russian melanoma patients.
    Lyubchenko L; Emelyanova M; Shamanin V; Demidov L; Zasedatelev A; Nasedkina T
    Cancer Biomark; 2016; 16(1):153-60. PubMed ID: 26600396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B; Kandiloğlu G; Akalin T
    Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
    Larsen AC
    Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAF V600E mutation-specific antibody: A review.
    Ritterhouse LL; Barletta JA
    Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma.
    Aksenenko MB; Kirichenko AK; Ruksha TG
    Pathol Res Pract; 2015 Jul; 211(7):521-7. PubMed ID: 25888143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of BRAF mutations in primary melanoma growth rate and survival.
    Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
    Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
    Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
    Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha.
    Tas F; Erturk K
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):521-526. PubMed ID: 30997532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
    J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.